Skip to content
DataLookout
Menu

NCT05841667

Impact of CES1 Genotype on Remimazolam

StatusUnknown
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Notable Primary and study completion dates: Dec 31, 2024 to Dec 31, 2025
    • Eligibility criteria revised
    v3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Dec 31, 2023 to Dec 31, 2024
    • Start date changed from estimate of May 15, 2023 to Sep 6, 2023
    • Study sites: 0 to 1
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Dose-adjusted steady-state concentration of remimazolam
Timeframe: Immediately before the initiation of remimazolam administration ~ 120 minutes after the cessation of remimazolam
Maintenance dose of remimazolam for maintaining general anesthesia
Timeframe: Immediately before the initiation of remimazolam administration ~ 120 minutes after the cessation of remimazolam
Total dose of remimazolam used to induce general anesthesia
Timeframe: Initiation of remimazolam administration ~ 5 minutes after start of remimazolam

Secondary (22)

Time to LOC after remimazolam administration during anesthesia induction
Time to bispectral index(BIS) < 60 after remimazolam administration during anesthesia induction
Changes in BIS during induction and maintenance of anesthesia
Percentage maintained BIS >60 during general anesthesia
Changes in BIS during anesthesia induction and maintenance
Show 17 moreShow less
Postanesthesia care unit (PACU) length of stay
Emergence delirium
Resedation
Precipitation
Injection pain caused by remimazolam administration
Adverse events up to 48 hours after surgery
Endogenous metabolites that occur as remimazolam is metabolized in the body (This is an exploratory check, meaning we do not know in advance what substances will be found)
Total dose of remimazolam during general anesthesia
Total dose of remifentanil during general anesthesia
Operation time
Anesthesia time
Flumazenil dosage
Pain score in PACU
Analgesic usage in PACU
Delirium
Postoperative complications
Hospital stay after surgery

Arms and interventions

CES1 without or without single nucleotide polymorphism (SNP)

We will determine the CES1 genotype of participants through a laboratory test. Several different types of SNPs can be identified, and analyses can be further stratified by CES1 SNP type.

Drugs: Remimazolam besylate

Sites

1 site in 1 country

  • Korea University Guro HospitalSeoul, South Korea